钆塞酸增强MRI与扩散加权成像诊断肝细胞癌早期复发的效能
前瞻性纳入34例肝硬化且经切除或消融后完全缓解的早期肝细胞癌患者,随访 extracellular 对比剂MRI 检出动脉期强化无廓清的新病灶后行DWI和钆塞酸增强MRI。共评估53个新动脉期强化灶,肝胆期低信号联合DWI高信号诊断肝细胞癌复发的敏感度54.8%、特异度90.9%、阳性预测值95.8%、阴性预测值34.5%。
要点
- 肝胆期低信号联合DWI高信号诊断早期富血供肝细胞癌复发特异度90.9%、阳性预测值95.8%,但敏感度仅54.8%。
- 对于 extracellular 对比剂MRI 表现不明确的新发动脉期强化灶,钆塞酸增强MRI联合DWI可能有助于鉴别早期富血供肝细胞癌复发。
- 联合征象可能帮助筛选适合挽救治疗的患者。
核心结论
- 在细胞外对比剂MRI常规标准不能确诊的肝硬化肝脏中,肝胆期低信号联合DWI高信号具有最高特异度和阳性预测值,可在确诊前最优检出肝细胞癌复发。
研究设计与样本
- 前瞻性研究,2014年至2017年纳入34例经切除和/或消融后完全缓解的肝硬化早期肝细胞癌患者,随访细胞外对比剂MRI检出动脉期强化无廓清的新病灶后行DWI和钆塞酸增强MRI,由两名阅片者分析动态各期及DWI信号强度,最终诊断由组织学或随访细胞外对比剂MRI确立。
关键影像表现/征象
- 评估53个新发动脉期强化灶,中位大小10 mm(IQR 9–14 mm)。
- 最终诊断经组织病理学确立15个(35.7%)病灶、经细胞外对比剂MRI随访确立27个(64.3%)病灶。
- 最终诊断为肝细胞癌42个(79.2%)、良性病变11个(21.8%)。
诊断标准与关键数值
- 肝胆期低信号联合DWI高信号诊断肝细胞癌复发:敏感度54.8%、特异度90.9%、阳性预测值95.8%、阴性预测值34.5%。
临床应用与阅片要点
- 作者认为,对于有肝细胞癌复发风险、细胞外对比剂MRI表现不明确的新发动脉期强化灶,钆塞酸增强MRI联合DWI可能改善与早期富血供肝细胞癌复发的鉴别。
- 肝胆期低信号联合DWI高信号具有高特异度和阳性预测值但敏感度有限,联合征象可能帮助筛选适合挽救治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine the diagnostic accuracy and predictive value of gadoxetic acid liver MRI (Gd-EOB-DTPA MRI) alone or in combination with diffusion-weighted imaging (DWI) as a second-line tool for detecting early hepatocellular carcinoma (HCC) recurrence in cirrhotic patients with previous HCC treated with resection or ablation.
METHODS: Between 2014 and 2017, we prospectively included 34 cirrhotic patients with complete response to resection and/or ablation of early HCC in whom a new focal lesion enhancing in the arterial phase without washout was detected during follow-up with EC-MRI. After signing the informed consent, all patients underwent DWI and Gd-EOB-DTPA MRI; two readers analyzed signal intensities on each phase of dynamic study and on DWI. The final diagnosis was established by histology or follow-up EC-MRI. We used cross-tabulation to calculate indices of diagnostic accuracy.
RESULTS: We evaluated 34 patients (7 women; 73.5% with hepatitis C virus) with a total of 53 new arterial-phase-enhancing foci (median size, 10 [IQR 9-14] mm). The final diagnosis, reached by histopathology in 15 (35.7%) lesions and EC-MR follow-up in 27 (64.3%), was HCC in 42 (79.2%) and benign conditions in 11 (21.8%). Hepatobiliary-phase hypointensity on Gd-EOB-DTPA MRI plus hyperintensity on DWI yielded 54.8% sensitivity, 90.9% specificity, 95.8% positive predictive value, and 34.5% negative predictive value for diagnosing HCC recurrence.
CONCLUSION: Among potential indices, combining hypointensity on hepatobiliary-phase Gd-EOB-DTPA MRI and hyperintensity on DWI has the highest specificity and positive predictive value to optimally detect HCC recurrence prior to confident diagnosis by conventional imaging criteria on EC-MRI in cirrhotic liver.
KEY POINTS: • In patients at risk of HCC recurrence, the use of gadoxetic acid liver MRI and DWI may improve the differentiation of unspecific new arterial-enhancing foci from early hypervascular HCC recurrence in patients with non-conclusive findings on extracellular liver MRI. • Combined findings on hepatobiliary-phase gadoxetic acid-enhanced liver MRI and DWI had high specificity (90.9%) and positive predictive value (95.8%) for detecting early hypervascular HCC recurrence, but limited sensitivity. • Combining hepatobiliary-phase hypointensity on gadoxetic acid MRI and hyperintensity on diffusion-weighted imaging allows early diagnosis of hypervascular hepatocellular carcinoma and may help select patients for salvage therapy.
引用
- Rimola J, Forner A, Sapena V, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol. 2019. PMID: 31372783. doi:10.1007/s00330-019-06351-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。